Blocking TNF production could offer a more effective solution for the treatment of COVID-19.
Researchers at Johns Hopkins Medicine identified a protein – known as factor D – that appears essential to the inflammatory process of SARS-CoV-2, the virus that causes Covid-19.
In a Phase III study, the biologic Dupixent met primary and all key secondary endpoints in children ages 6 to 11 who have uncontrolled moderate-to-severe asthma.
Topline results from a 28-week Phase IIb trial show that lenabasum, a novel oral small molecule developed by Massachusetts-based Corbus Pharmaceuticals, did not reduce the rate of new pulmonary exacerbations compared with placebo in patients with cystic fibrosis (CF).
Researchers from Aarhus University in Denmark published research indicating that Parkinson’s disease is actually two types of the disease.
A lower supply of a certain type of immune cell in older people that is critical to fighting foreign invaders may help explain their vulnerability to severe Covid-19, scientists say. An antiseptic nasal spray containing povidone-iodine may help curb transmission of the new coronavirus, preliminary research suggests.
Sanofi and Regeneron said results from a Phase III open-label extension trial showed that the safety and efficacy profile observed in previous Dupixent trials were maintained for up to three years in adults and adolescents with moderate-to-severe asthma.
The U.S. Food and Drug Administration approved Italy-based Cassiopea SpA’s acne treatment Winlevi (clascoterone cream 1%).
According to a study published in Nature Communications, enzymes that are used by bacteria to break down mucus in the gut can potentially be useful biomarkers for intestinal diseases.
Biotech company Kancera AB received clearance from the Swedish Medical Products Agency to initiate a clinical trial of KAND567, which blocks the Fractalkine receptor that plays a major role in triggering the body’s inflammatory process.